---
title: "Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants"
analyst: amantonio
header: 'A few more examples'
article:
  type: article
  authors: Vesikari
  year: 2011
  journal: Pediatr Infect Dis J
  link: https://www.ncbi.nlm.nih.gov/pubmed/21552183
  pubmed: 21552183
---

Clinical trials of the Recombivax-HB vaccine against Hepatitis B. Safety was tested for 14 days.
77% of children had adverse events. 28 children (1.6%) had serious adverse events. One child died (SIDS). Authors report that probably his death was not related to the vaccination.
